ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

CVSG Cvs Group Plc

994.00
-6.00 (-0.60%)
Last Updated: 08:00:26
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Cvs Group Plc LSE:CVSG London Ordinary Share GB00B2863827 ORD 0.2P
  Price Change % Change Share Price Shares Traded Last Trade
  -6.00 -0.60% 994.00 1,976 08:00:26
Bid Price Offer Price High Price Low Price Open Price
990.50 1,002.00 1,003.00 994.00 1,002.00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Veterinary Svcs-animal Specs 608.3M 41.9M 0.5843 17.11 717.13M
Last Trade Time Trade Type Trade Size Trade Price Currency
08:01:01 O 109 997.462 GBX

Cvs (CVSG) Latest News

Cvs (CVSG) Discussions and Chat

Cvs Forums and Chat

Date Time Title Posts
18/3/202413:38CVS Group: VETS,All things bright and beautiful905
07/10/201919:38Concerns founded?33

Add a New Thread

Cvs (CVSG) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
08:01:01997.461091,087.23O
08:00:271,000.00110.00O
08:00:14994.0052516.88AT
08:00:11995.001231,223.85AT
08:00:11995.0097965.15AT

Cvs (CVSG) Top Chat Posts

Top Posts
Posted at 18/3/2024 08:20 by Cvs Daily Update
Cvs Group Plc is listed in the Veterinary Svcs-animal Specs sector of the London Stock Exchange with ticker CVSG. The last closing price for Cvs was 1,000p.
Cvs currently has 71,712,970 shares in issue. The market capitalisation of Cvs is £717,129,700.
Cvs has a price to earnings ratio (PE ratio) of 17.11.
This morning CVSG shares opened at -
Posted at 18/3/2024 13:38 by roddyb
I am hoping this will recover but there are very valid concerns as to how these companies price their services and fail to disclose pricing and dissuade pet owners from shopping around. The CMA are going to land some blows just as they did with Dignity Funeral services.

Management will be scared to do share buybacks during the CMA investigation and probably scared to pay an increased dividend? They will certainly be delaying purchasing any more UK vet practices.

Not looking good for the next 6 months.
Posted at 16/3/2024 15:18 by dogwalker
Re 902 above, it'd be interesting to know Liberum's recommendation & target price now, now that the CMA have decided to proceed.
Posted at 16/3/2024 12:05 by wallywoo
IVC Evidensia are the biggest player in the UK market with around 1000 UK locations (2500 worldwide). They are a private equity outfit, therefore, not mentioned in press. But are more then 5x the size of cvs (ww).


To me, the trend towards larger groups is all about economies of scale, not about exploiting a monopoly (most small vets have a near monopoly in their location anyway). I think it is likely any competition authority will come to the same conclusion. Making these practices cut their price will just close the smaller, less efficient vets and not help the market.


For those reasons I think this will recover over the next few months and have invested here yesterday at 1005. This share price drop could also attract a speculative bid imho. The USA are well ahead of UK, Europe, Australia with large vet groups. I am sure they will be looking at cvsg with interest now!! Huge companies such as Mars (already own 180 uk practices), Walmart etc are in this sector.
Posted at 16/3/2024 06:37 by lomax99
CVS discount is too high, says LiberumThe discount at which veterinary group CVS (CVSG) trades is 'too high', given the competition watchdog's review into vet practices is likely to prove there is no case to answer, says Liberum.Analyst Seb Jantet retained his 'buy' recommendation and target price of £22 on the stock, which gained 1.4% to £14.92 at the end of last week after its interim results. The shares have shed 21% over the year following the Competitions & Markets Authority (CMA) decision to investigate whether vets were providing consumers with value for money.Jantet said there was not a lot of new information in the result but added that 'we are still waiting for the most important piece of information, being the CMA's initial decision which is still expected in early 2024'.'While the shares have recovered a little over the last few months, they are still trading on undemanding multiples both in absolute terms and in relation to historic ratings, on a current year 2024 embedded value to pre-tax profit multiple of 9.9 times,' he said.'While we accept that the CMA uncertainty warrants a discount over the historic rating of around 15 times, the discount looks too high to us, especially given our view that there is a good chance the CMA will conclude there isn't a case to answer when it next updates.'
Posted at 13/3/2024 05:29 by undervaluedassets
Well we now have a 2017 share price

And in 2017 the company had EPS of 18p, profits of 14 million and a 271 million turnover.

Is that what we should expect? instead of the pencilled 80-90p in earnings on 50-90 million in profit on a turnover of 670 million?

I do not see that being the case...

Ergo .. cheap

The market panicked today. In the past, I have done well out of buying into panics.
Posted at 12/3/2024 13:11 by 1c3479z
CMA could bear down on cremation fees, drug pricing and lab investigations. These could be the most profitable part of the vet practice? don't know as not in the profession. Can't do anything about vet's time or the range of investigations ordered though could put a price cap on common radiology and lab investigations I guess.
Posted at 12/3/2024 09:23 by undervaluedassets
Overdone. This is old news re-issued.

Properly cheap now

Have watched and admired CVSG for years but the multiple was always too big for me. (pe of 127 and 80 in 2020 and 2021 respectively)

On a current pe of 20 and with a pe of 15 pencilled for 2024 this is now a looks a reasonable punt

The 16 million pet owners are a huge addressable market which is not disappearing and into which the company can grow.
Posted at 26/1/2024 11:31 by iamnotanumber6
Berenberg believes CVS can deliver double-digit earnings growth
Veterinary services provider CVS Group (CVSG) is on track with its plan to grow, invest and acquire, a story that remains ‘highly attractive’, says Berenberg.

Analyst Calum Battersby retained his ‘buy’ recommendation and target price of £23.70 on the stock, which was trading at £16.73 on Thursday.

A first-half trading update for the six months to the end of 2023 showed the group’s ‘strong performance’ has continued, Battersby said, with 6% like-for-like revenue growth, stable year-on-year margins and a further 5.4% revenue contribution from acquisitions.

Battersby said the company’s growth strategy is ‘clearly working’ as it enjoyed a ‘combination of strong organic growth, investments in practice refurbishments and relocations, acquisitions in the UK and acquisitions in Australia’.

Although the market is currently focusing on the next update from the Competition and Markets Authority which is looking into value for money offered by vets, Battersby said the ‘underlying CVS story remains highly attractive’ and said investors ‘can expect double-digit compounding earnings growth for the foreseeable future’.
Posted at 21/9/2023 12:43 by kalai1
CVS Group posted impressive Final Results for the year 30th June this morning. Revenue was up 9.8% to £608.3m, operating profit was up 45.6% to £62.3m, basic EPS was up 62.4% to £58.8m. Adjusted numbers were less stellar but still solid with adjusted EBITDA up 13% to £121.4m, adjusted EPS up 11.9% to 96p. The balance sheet remains solid despite the fact that Leverage increased to 0.73x as a result of the acquisition of Quality Pet Care Ltd. Net debt was up to £74m. Valuation is starting to look quite attractive with forward PE ratio at 15.9x, which is comfortably below the 23.6x trailing 12-month low for the share since FY17. The share price lacks positive momentum following its early September collapse following the Competition and Markets Authority launch of a review into the UK veterinary services market for household pets. CVSG remains a share to monitor for the time being, but company specific factors point to an increasingly attractive investment case...

...from WealthOracle
Posted at 07/9/2023 10:40 by maywillow
Michele Maatouk
Sharecast News
07 Sep, 2023 09:35 07 Sep, 2023 09:41


Pets at Home, CVS tumble as CMA launches review of vet services


Shares of Pets at Home and CVS Group tumbled on Thursday after the Competition and Markets Authority said it was launching a probe into the £2bn veterinary services market for household pets.




The competition watchdog said it will explore how well the market is working for pet owners and whether they are receiving the information they need at the right time to get appropriate treatment for their pets.

The CMA said it was keen to hear more about pet owners’ and vet practitioners’ experiences of pricing of services, including whether pet owners were aware of how much a treatment would cost, and how they pay for it.

It also wants to hear about how prescriptions and medication for pets are arranged and sold and how pet owners choose a vet surgery - whether they are aware that their vet may be part of a larger chain which might also own other surgeries in the area.

The use of out-of-hours and emergency vet services where options might be limited will also be looked into.

CMA chief executive Sarah Cardell said: "Caring for an ill pet can create real financial pressure, particularly alongside other cost of living concerns. It’s really important that people get clear information and pricing to help them make the right choices.






"There has been a lot of consolidation in the vet industry in recent years, so now is the right time to take a look at how the market is working.

"When a pet is unwell, they often need urgent treatment, which means that pet owners may not shop around for the best deal, like they do with other services. This means they may not have the relevant information to make informed decisions at what can be a distressing time. We want to hear from pet owners and people who work in the sector about their experiences."

Pets at Home owns veterinary groups Companion Care Vets and Vets4Pets and has a network of more than 450 vet practices across the UK. CVS Group, meanwhile, is one of the largest integrated veterinary services providers in the UK.

At 0925 BST, Pets shares were down 11.2% at 336.20p. Shares of AIM-listed vet services provider CVS Group were down 29% at 1,479.00p.

Russ Mould, investment director at AJ Bell, said: "Being in the pets and vet space has felt like a healthy place to be in recent years. That’s been reflected in strong share prices for the likes of vet group CVS and Pets at Home which has its own veterinary arm within a broader retail and grooming offering.

"Britons love their animal companions and are willing to pay up to keep them healthy and happy.

"News that the competition authorities are looking into the rising costs and potentially anti-competitive practices in the industry has set the cat among the pigeons when it comes to the share prices of CVS and Pets at Home.

"The sell-off seen today could be an overreaction, although the CMA review looks to be wide-ranging. The problem for both businesses is the process is likely to be time-consuming and, with a further update not due until early 2024, it could weigh on both stocks for some time to come."
Cvs share price data is direct from the London Stock Exchange

Your Recent History

Delayed Upgrade Clock

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: +44 (0) 203 8794 460 | support@advfn.com